Articles By RheumNow
AS Diagnosis Linked to CVD Risk
By RheumNow
Prevalent patients with ankylosing spondylitis (AS) face a 30–50% increased risk of acute coronary, cerebrovascular, and thromboembolic events compared with the general population.
Read Article
Dramatic Results for Interferon Blocker in SLE
By RheumNow
Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.
Read Article
No Increased Risk of Colitis Flares in Secukinumab Trials
By RheumNow
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Read Article
Tendon Inflammation May Signal Early RA
By RheumNow
Tenosynovitis may represent a preclinical phase of rheumatoid arthritis (RA).
Read Article
JIA Women at Risk of Heart Disease
By RheumNow
Women with a history of juvenile idiopathic arthritis (JIA) are more than twice as likely as those without this condition to be diagnosed with heart disease, according to the results of a new study.
Read Article
Doctors Need to See the Forest, Not Just the Trees
By RheumNow
Doctors have an interesting problem. They have an ingrained professional obsessive-compulsive habit; they fixate on the care of individual patients and on the science of healing. This is an admirable trait; it results in high-quality care. However, when physicians need to change their attention from healer to leader, from medicine to the business of medicine, from healthcare to the healthcare system, they falter. Stuck in silos, they fail to adjust their focus. They resist systemic innovation. Because they cannot flip, they flop.
Read Article
CV Events Strike Early in Lupus
By RheumNow
Patients with systemic lupus erythematosus are at risk of cardiovascular events early in the course of disease -- and even before their lupus is diagnosed, an international study found.
Read Article
A Rocky Start for Biosimilar Inflectra?
By RheumNow
This week, when the FDA approved the biosimilar drug Inflectra as an alternative to infliximab (Remicade), it was only the second biosimilar to be granted approval in the United States, and was the fi
Read Article
Baricitinib Benefits Refractory RA
By RheumNow
The small molecule oral JAK inhibitor baricitinib was effective for patients with highly refractory rheumatoid arthritis, a phase III study found.
Read Article
DMARDs Combo Cuts Time to First Remission in RA
By RheumNow
A three-therapy protocol did not prove superior for achieving remission in rheumatoid arthritis (RA) patients after 1 year, but the regimen did lead to a shorter time until first remission versus a step-up approach, according to an analysis of the DREAM registry.
Read Article